Our Bond, Inc. Free cash flow decreased by 154.2% to -$4.42M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 154.2%, from -$1.74M to -$4.42M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | -$2.05M | -$2.05M | -$2.05M | -$2.05M | -$1.74M | -$1.74M | -$1.74M | -$1.74M | -$4.42M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +15.4% | +0.0% | +0.0% | +0.0% | -154.2% |
| YoY Change | — | — | — | — | +15.4% | +15.4% | +15.4% | +15.4% | -154.2% |